CG Oncology, Inc. (NASDAQ:CGON) Receives $63.88 Consensus PT from Analysts

CG Oncology, Inc. (NASDAQ:CGON) has been given a consensus recommendation of “Buy” by the ten research firms that are covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $63.88.

Several research firms recently commented on CGON. TD Cowen began coverage on CG Oncology in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and set a $75.00 price target on shares of CG Oncology in a report on Friday, January 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a report on Friday, December 6th. Finally, Morgan Stanley reissued an “overweight” rating and set a $55.00 target price on shares of CG Oncology in a research note on Friday, March 7th.

CG Oncology Stock Performance

CG Oncology stock opened at $27.67 on Friday. The firm’s 50-day moving average is $28.32 and its 200-day moving average is $32.40. CG Oncology has a 1 year low of $23.91 and a 1 year high of $46.99.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Investors Weigh In On CG Oncology

Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in CG Oncology during the 4th quarter worth approximately $41,000. Amalgamated Bank boosted its position in shares of CG Oncology by 107.6% in the third quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock worth $61,000 after buying an additional 840 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CG Oncology during the fourth quarter valued at $68,000. KLP Kapitalforvaltning AS purchased a new position in shares of CG Oncology during the fourth quarter valued at $100,000. Finally, Federated Hermes Inc. acquired a new position in CG Oncology during the fourth quarter valued at $172,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.